Home/Pipeline/Advanced Asthma Products

Advanced Asthma Products

Asthma

Not DisclosedActive

Key Facts

Indication

Asthma

Phase

Not Disclosed

Status

Active

Company

Polpharma

About Polpharma

Polpharma is a dominant, privately-held generic drug manufacturer in Poland and a key regional player in CEE and CIS markets. With over 4,300 employees, five manufacturing plants, and three R&D centers, it produces approximately 400 million medicine packages annually, holding a ~12.5% share of the Polish pharmacy market and a ~33% share of the hospital market. The company is expanding its international presence, notably with a new office in India, and is investing in innovative drug development in areas like ophthalmology and asthma while maintaining a strong foundation in generics and APIs.

View full company profile

Therapeutic Areas

Broad Generics Ophthalmology Asthma Hospital Care

Other Asthma Drugs

Drug	Company	Phase	Status
Technegas® for Asthma	Cyclomedica	Phase 2	Active
Asthma Candidate	Teva	Phase 3	Active
Montelukast Amorphous Form	Morepen Laboratories	Phase-2	Active
Chitinase Inhibitor	Lead Discovery Siena	Discovery	Active
RIG-101	RIGImmune	Pre-clinical	Active
SKB378	Klus Pharma	Phase 1	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
Asthma Trial	Science 37	Phase 3	Completed/Highlighted
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Digital Biomarker for Asthma	electronRx	Early Development	Active
Flutiform	KYORIN Pharmaceutical	Marketed	Active